Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

A 14-day repeat dose oral gavage range-finding study of a first-in-class CDI investigational antibiotic, in rats.

Sibley K, Chen J, Koetzner L, Mendes O, Kimzey A, Lansita J, Boulos RA.

Sci Rep. 2019 Jan 17;9(1):158. doi: 10.1038/s41598-018-36690-9.

2.

Absence of adverse effects following the gavage administration of methyl propyl trisulfide to Sprague-Dawley rats for 90 days.

Bastaki M, Aubanel M, Cachet T, Demyttenaere J, Diop MM, Harman CL, Hayashi SM, Koetzner L, Krammer G, Li X, Llewellyn C, Mendes O, Renskers KJ, Schnabel J, Smith BPC, Taylor SV.

Food Chem Toxicol. 2018 Oct;120:544-551. doi: 10.1016/j.fct.2018.07.056. Epub 2018 Aug 1.

PMID:
30075317
3.

In vitro and in vivo safety evaluation of Nephure™.

Cowley H, Yan Q, Koetzner L, Dolan L, Nordwald E, Cowley AB.

Regul Toxicol Pharmacol. 2017 Jun;86:241-252. doi: 10.1016/j.yrtph.2017.03.016. Epub 2017 Mar 18.

4.

Robustness of arterial blood gas analysis for assessment of respiratory safety pharmacology in rats.

Whiteside GT, Hummel M, Boulet J, Beyenhof JD, Strenkowski B, John JD, Knappenberger T, Maselli H, Koetzner L.

J Pharmacol Toxicol Methods. 2016 Mar-Apr;78:32-41. doi: 10.1016/j.vascn.2015.11.001. Epub 2015 Nov 14.

PMID:
26589431
5.

Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats.

Reimer RA, Grover GJ, Koetzner L, Gahler RJ, Lyon MR, Wood S.

J Endocrinol. 2014 Feb 10;220(3):361-73. doi: 10.1530/JOE-13-0484. Print 2014 Mar.

PMID:
24389593
6.

A primer for best practices in tissue preparation for bioanalysis.

Kemper CJ, Koetzner L, Koleto M.

Bioanalysis. 2012 Nov;4(21):2621-36. doi: 10.4155/bio.12.230. Review.

PMID:
23173796
7.

Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.

Reimer RA, Grover GJ, Koetzner L, Gahler RJ, Juneja P, Lyon MR, Wood S.

J Nutr. 2012 Oct;142(10):1812-20. Epub 2012 Aug 22.

8.

Effects of the Soluble Fiber Complex PolyGlycopleX on Glucose Homeostasis and Body Weight in Young Zucker Diabetic Rats.

Grover GJ, Koetzner L, Wicks J, Gahler RJ, Lyon MR, Reimer RA, Wood S.

Front Pharmacol. 2011 Sep 7;2:47. doi: 10.3389/fphar.2011.00047. eCollection 2011.

9.

The soluble fiber complex PolyGlycopleX lowers serum triglycerides and reduces hepatic steatosis in high-sucrose-fed rats.

Reimer RA, Grover GJ, Koetzner L, Gahler RJ, Lyon MR, Wood S.

Nutr Res. 2011 Apr;31(4):296-301. doi: 10.1016/j.nutres.2011.03.012.

PMID:
21530803
10.

Effects of the soluble fiber complex PolyGlycopleX® (PGX®) on glycemic control, insulin secretion, and GLP-1 levels in Zucker diabetic rats.

Grover GJ, Koetzner L, Wicks J, Gahler RJ, Lyon MR, Reimer RA, Wood S.

Life Sci. 2011 Feb 28;88(9-10):392-9. doi: 10.1016/j.lfs.2010.11.014. Epub 2010 Nov 30.

PMID:
21115020
11.

Plant-derived polysaccharide supplements inhibit dextran sulfate sodium-induced colitis in the rat.

Koetzner L, Grover G, Boulet J, Jacoby HI.

Dig Dis Sci. 2010 May;55(5):1278-85. doi: 10.1007/s10620-009-0848-7. Epub 2009 Jun 10.

12.

Rapid and sensitive determination of acetylsalicylic acid and salicylic acid in plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study.

Xu X, Koetzner L, Boulet J, Maselli H, Beyenhof J, Grover G.

Biomed Chromatogr. 2009 Sep;23(9):973-9. doi: 10.1002/bmc.1209.

PMID:
19358313
13.

Energetic signalling in the control of mitochondrial F1F0 ATP synthase activity in health and disease.

Grover GJ, Marone PA, Koetzner L, Seto-Young D.

Int J Biochem Cell Biol. 2008;40(12):2698-701. doi: 10.1016/j.biocel.2008.06.013. Epub 2008 Jul 30. Review.

PMID:
18707016
14.

Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.

Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT.

Neuropharmacology. 2005 Apr;48(5):658-72.

PMID:
15814101
15.

Intrathecal protease-activated receptor stimulation produces thermal hyperalgesia through spinal cyclooxygenase activity.

Koetzner L, Gregory JA, Yaksh TL.

J Pharmacol Exp Ther. 2004 Oct;311(1):356-63. Epub 2004 Jun 2.

PMID:
15175421
16.
17.

Characterization of equine butyrylcholinesterase disposition in the mouse.

Koetzner L, Woods JH.

Drug Metab Dispos. 2002 Jun;30(6):724-30.

PMID:
12019201
18.

Characterization of butyrylcholinesterase antagonism of cocaine-induced hyperactivity.

Koetzner L, Woods JH.

Drug Metab Dispos. 2002 Jun;30(6):716-23.

PMID:
12019200
19.

Tetrabenazine fails to antagonize a behavioral effect of cocaine in rhesus monkeys.

Koetzner L, Sumpter TL, Woods JH.

Pharmacol Biochem Behav. 2002 Jan-Feb;71(1-2):1-5.

PMID:
11812502
20.

Titer-dependent antagonism of cocaine following active immunization in rhesus monkeys.

Koetzner L, Deng S, Sumpter TL, Weisslitz M, Abner RT, Landry DW, Woods JH.

J Pharmacol Exp Ther. 2001 Mar;296(3):789-96.

PMID:
11181908
21.

Evaluation of in vivo interactions in mice between flurazepam and two neuroactive steroids.

Deutsch SI, Rosse RB, Steinberg K, Morn C, Koetzner L, Riggs R, Mastropaolo J.

Pharmacol Biochem Behav. 1996 Nov;55(3):323-6.

PMID:
8951972
22.

The competitive NMDA antagonist CPP blocks MK-801-elicited popping behavior in mice.

Deutsch SI, Rosse RB, Riggs RL, Koetzner L, Mastropaolo J.

Neuropsychopharmacology. 1996 Oct;15(4):329-31.

23.

7-Nitroindazole and methylene blue, inhibitors of neuronal nitric oxide synthase and NO-stimulated guanylate cyclase, block MK-801-elicited behaviors in mice.

Deutsch SI, Rosse RB, Paul SM, Tomasino V, Koetzner L, Morn CB, Mastropaolo J.

Neuropsychopharmacology. 1996 Jul;15(1):37-43.

24.

Discriminative stimulus effects of dopaminergic agents in rhesus monkeys.

Koetzner L, Riley AL, Glowa JR.

Pharmacol Biochem Behav. 1996 Jun;54(2):517-23.

PMID:
8743617
25.

Selective cyclodextrin inhibition of alfaxolone-induced ataxia.

Koetzner L, Riggs RL, Mastropaolo J, Deutsch SI.

J Pharm Pharmacol. 1996 May;48(5):529-31.

PMID:
8799881
26.

Facilitating role of m-chlorophenylbiguanide in a cocaine discrimination.

Koetzner L, Mastropaolo J, Deutsch SI.

Pharmacol Biochem Behav. 1995 Dec;52(4):815-8.

PMID:
8587924
27.

Computerized measurement of MK-801-elicited popping and hyperactivity in mice.

Rosse RB, Mastropaolo J, Sussman DM, Koetzner L, Morn CB, Deutsch SI.

Clin Neuropharmacol. 1995 Oct;18(5):448-57.

PMID:
8665559
28.

MK-801 alters the GABAA receptor complex and potentiates flurazepam's antiseizure efficacy.

Deutsch SI, Park CH, Lukacs LG, Morn C, Koetzner L, Mastropaolo J.

Pharmacol Biochem Behav. 1995 Aug;51(4):909-15.

PMID:
7675876
29.

Interference with nitric oxide production and action potentiates the antiseizure efficacy of flurazepam.

Deutsch SI, Rosse RB, Morn C, Koetzner L, Mastropaolo J.

Pharmacol Biochem Behav. 1995 May;51(1):133-7.

PMID:
7617724

Supplemental Content

Loading ...
Support Center